Get 40% Off
🔥 This hedge fund gained 26.16% in the last month. Get their top stocks with our free stock ideas tool.See stock ideas

Quest Diagnostics, LabCorp Defend Lab Fee Suit Against HHS

Published 12/18/2017, 08:54 PM
Updated 07/09/2023, 06:31 AM
LH
-
DGX
-
RVTY
-
DVA
-

Healthcare diagnostic majors and arch-rivals Quest Diagnostics Incorporated (NYSE:DGX) and Laboratory Corporation of America Holdings (NYSE:LH) or LabCorp are on the same page regarding the much contentious topic of Protecting Access to Medicare Act (“PAMA”) on clinical lab fee schedule.

Recently, both the companies as members of the American Clinical Laboratory Association (“ACLA”) have come forward to support a lawsuit filed by ACLA against the Acting Secretary of the U.S. Department of Health and Human Services (“HHS”). The lawsuit charged that the Centers for Medicare & Medicaid Services (“CMS”), operating under the purview of HHS, have failed to follow a congressional directive to implement a market-based laboratory payment system.

Per the lawsuit claims, CMS ignored the Congress directives stated under PAMA and instituted a highly flawed data reporting process of setting market rates in advance.

This prohibited the overwhelming majority of laboratories from reporting the private payer data used to determine Medicare rates for lab tests. The move has instead resulted in new Medicare lab rates, which are not market-specific. Hence, the entire process clearly demonstrates CMS’ failure to protect access to laboratory services for Medicare beneficiaries.

Per the press release from LabCorp, if the new rates are allowed to come into effect, it will affect the Medicare beneficiaries as well as disrupt the healthcare system. Per Quest diagnostics, “this flawed process could cause serious financial harm to potentially thousands of hospitals, independent and physician office laboratories and make it harder for Medicare beneficiaries to get access to medical testing, particularly in remote rural areas and in nursing homes that depend on laboratory testing services”.

Earlier during the third quarter earnings release, both LabCorp and Quest Diagnostics had issued certain objections in response to the Sep 22 publication by CMS on the proposed 2018 Medicare reimbursement rates for clinical laboratory tests under the Clinical Lab Fee Schedule (CLFS) mandated by PAMA. Per the companies, only 1% of all laboratories submitted data and over 99% of hospitals and physician office laboratories were prevented from reporting their rates.

The above-mentioned 1% of laboratories majorly denoted independent labs. To convey the severity of the situation in clear terms, Quest Diagnostics stated that based on data submitted through CMS, the company alone represented nearly 40% of all the market data that CMS collected.

Among other possibly badly hit clinical laboratories, thanks to the latest CMS mandate on clinical lab fee schedule, two names emerge as DaVita Inc. (NYSE:DVA) and PerkinElmer, Inc. (NYSE:PKI) . While Quest Diagnostics, LabCorp and PerkinElmer carry a Zacks Rank #3 (Hold), DaVita has a Zacks Rank #5 (Strong Sell).

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Zacks Editor-in-Chief Goes "All In" on This Stock

Full disclosure, Kevin Matras now has more of his own money in one particular stock than in any other. He believes in its short-term profit potential and also in its prospects to more than double by 2019. Today he reveals and explains his surprising move in a new Special Report.

Download it free >>



PerkinElmer, Inc. (PKI): Free Stock Analysis Report

Quest Diagnostics Incorporated (DGX): Free Stock Analysis Report

DaVita HealthCare Partners Inc. (DVA): Free Stock Analysis Report

Laboratory Corporation of America Holdings (LH): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.